Loteprednol etabonate controls inflammation and IOP

Article

Loteprednol etabonate controls inflammation and reduces IOP fluctuation after cataract surgery, according to a recent study.

Loteprednol etabonate controls inflammation and reduces IOP fluctuation after cataract surgery, according to a recent study.

The comparative case series, led by Dr S. Lane, Associated Eye Care, Stillwater, Minnesota, USA, involved 88 patients. Loteprednol etabonate was given to 46 patients and prednisolone acetate was given to 42 patients. Both sets of patients also received bromfenac 0.09% and besifloxacin 0.6% after surgery.

Patients were excluded from the study if they had pre-existing medical conditions such as elevated IOP, retinopathy, maculopathy or uveitis. The outcome measures included visual acuity, IOP, and anterior chamber cell and flare intensity. The primary endpoint was the level of anterior chamber cell and flare intensity in all patients.

The two groups achieved equivalency with no significant differences throughout the 3-week follow-up period. Loteprednol etabonate reduced IOP fluctuation, compared to patients treated with prednisolone acetate. However, both treatment groups presented with controlled inflammation after cataract surgery.

The abstract can be found in the Journal of Cataract and Refractive Surgery.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.